NCT06713187

Interleukin23 in Systemic Lupus

Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Sohag University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .

Detailed description

for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients\&laboratory investigation included 1\_erythrocytic sedimentation rate.2\_complete blood count.3\_interleukin23 .4\_complement 3\&4.5\_Antinuclear Antibodies.6\_Anti double stranded antibodies.7\_full basic biochemical test(24 urine protien)8\_high resolution computed tomography.

Conditions

• Systemic Lupus Erythematosus Related Interstial Lung Disease

Interventions

Type	Name	Description
BIOLOGICAL	interleukin 23	assessment of interleukin 23 in Sera of patients using ELIZA

Timeline

• Start date: 2025-05-01
• Primary completion: 2025-08-01
• Completion: 2026-06-01
• First posted: 2024-12-03
• Last updated: 2024-12-03

Locations

2 sites across 1 country: Egypt